Aromatase inhibitors (AIs) are indicated in the treatment of hormone-receptive breast cancer in postmenopausal women in various settings. Studies have shown that they are effective when used asÂ adjuvant therapy to chemotherapy and surgery in metastatic estrogen-dependent breast cancer. Their use in preventative and adjuvant therapies for other conditions is currently under investigation.

**FDA Approved Indications**

- Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer

- First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer

- Second-line treatment of advanced breast cancer that has progressed on Tamoxifen therapy

- Treatment of male gynecomastia

- Second-line treatment for the prevention of hormone-receptor-positive breast cancer

**FDA Non-approved Indications**

- Treatment of benign conditions like cyclical breast pain and recurrent fibrocystic disease

- Treatment of symptomatic myomas and endometriosis as an alternative to surgical intervention

- Ovulation induction in the treatment of infertility

- Treatment of male breast cancer

- Treatment of prostate cancer

- Treatment of late-onset hypogonadism or partial androgen deficiency, obesity-related hypogonadotropic hypogonadism, and male subfertility

- Treatment of rare pediatric conditions associated with sex steroid excess

- Treatment of boys with short stature and constitutional delay of puberty

- Prevention of the initial estrogen flare effect of gonadotropin-releasing hormone agonist treatment